BioPharmSignal logoBioPharmSignal

Biotech News

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

Foghorn Therapeutics (FHTX)Foghorn Therapeutics2026-06-25 13:46 ESTClinical readout

Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and ER+

Open original release

Related news

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

View all latest news

Foghorn Therapeutics

Foghorn Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

FHTXFoghorn Therapeutics2026-06-26 08:50 EST

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

FHTXFoghorn Therapeutics2026-06-26 08:50 EST

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

FHTXFoghorn Therapeutics2026-06-26 08:50 EST

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-06-26 08:50 EST

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-06-26 08:50 EST

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States